A randomised, double-blind, placebo-controlled, two-sequence, two-period, crossover study to evaluate the effect of SMP-028 on oral contraceptive pharmacokinetics in healthy female subjects
A Randomised, Double-Blind, Placebo-Controlled, Two-Sequence, Two-Period, Crossover Study to Evaluate the Effect of SMP-028 on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects - OC interaction study with SMP-028
A Phase 2, Multi-Centre, Randomised, Double Blind, Placebo Controlled Study Evaluating the Efficacy, Safety and Pharmacokinetics of Two Doses of a Candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg Once Daily), Administered in Combination With Ongoing Methotrexate Treatment in Patients With Active Rheumatoid Arthritis.
To compare the efficacy of SMP-114 (120 and 240 mg/d) versus placebo in terms of the percentage of patients meeting the American College of Rheumatology criteria for 20% improvement in RA (ACR20) at week 24. The study hypothesis would be to demonstrate that the use of methotrexate and SMP-114 is more efficacious than Methotrexate alone.
100 Clinical Results associated with Dainippon Sumitomo Pharma Europe LTd.
0 Patents (Medical) associated with Dainippon Sumitomo Pharma Europe LTd.
100 Deals associated with Dainippon Sumitomo Pharma Europe LTd.
100 Translational Medicine associated with Dainippon Sumitomo Pharma Europe LTd.